Stifel Cuts Price target on Argos Therapeutics (ARGS) Following 4Q15 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
March 29, 2016 6:12 PM EDTDURHAM, N.C., March 29, 2016 (GLOBE NEWSWIRE) -- In the release issued earlier today by Argos Therapeutics (Nasdaq: ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release... More
Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
March 29, 2016 4:30 PM EDT- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 Â
- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 Following Data Reviews in June and December 2015 -Â
- Established Scientific Advisory Board in July 2015 Â
- Early stage RCC trial of AGS-003 Commenced at Roswell Park Cancer Institute in July 2015 -Â
- Conference Call and Webcast Today, March 29th, at 4:30 p.m. ET -
DURHAM, N.C., March 29, 2016 (GLOBE NEWSWIRE) --... More
